The stock has a 36-month beta value of 3.04. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for ATHA is 33.69M, and at present, short sellers hold a 2.66% of that float. On June 12, 2025, the average trading volume of ATHA was 568.67K shares.
ATHA) stock’s latest price update
Athira Pharma Inc (NASDAQ: ATHA) has seen a decline in its stock price by -6.76 in relation to its previous close of 0.34. However, the company has experienced a -2.67% decline in its stock price over the last five trading sessions. accessnewswire.com reported 2025-06-04 that HIGHLIGHTS The 2025 Angilak Exploration Program will comprise ~10,000 m of diamond drilling with two objectives: Lac 50 Deposit – expansion of the footprint of uranium mineralization. Stepping out along strike and at depth from the 2024 Exploration Target (as defined below), which remains open and unconstrained.
ATHA’s Market Performance
ATHA’s stock has fallen by -2.67% in the past week, with a monthly rise of 18.96% and a quarterly drop of -2.07%. The volatility ratio for the week is 7.19% while the volatility levels for the last 30 days are 5.63% for Athira Pharma Inc The simple moving average for the past 20 days is 7.94% for ATHA’s stock, with a -40.46% simple moving average for the past 200 days.
Analysts’ Opinion of ATHA
Many brokerage firms have already submitted their reports for ATHA stocks, with Mizuho repeating the rating for ATHA by listing it as a “Neutral.” The predicted price for ATHA in the upcoming period, according to Mizuho is $0.50 based on the research report published on September 19, 2024 of the previous year 2024.
ATHA Trading at 15.74% from the 50-Day Moving Average
After a stumble in the market that brought ATHA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -91.25% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at ATHA starting from San Martin Javier, who sale 10,826 shares at the price of $0.56 back on Jan 02 ’25. After this action, San Martin Javier now owns 35,841 shares of Athira Pharma Inc, valued at $6,083 using the latest closing price.
Litton Mark James, the President and CEO of Athira Pharma Inc, sale 25,107 shares at $0.56 during a trade that took place back on Jan 02 ’25, which means that Litton Mark James is holding 242,591 shares at $14,108 based on the most recent closing price.
Stock Fundamentals for ATHA
The total capital return value is set at -2.18. Equity return is now at value -110.70, with -90.12 for asset returns.
Based on Athira Pharma Inc (ATHA), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -77.02.
Currently, EBITDA for the company is -95.97 million with net debt to EBITDA at 0.32. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.26.
Conclusion
To sum up, Athira Pharma Inc (ATHA) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
